EP-100

Esperance Pharmaceuticals Inc · Phase 2 active Small molecule

At a glance

Generic name	EP-100
Sponsor	Esperance Pharmaceuticals Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (PHASE2)
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EP-100 CI brief — competitive landscape report
EP-100 updates RSS · CI watch RSS
Esperance Pharmaceuticals Inc portfolio CI